Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) closed at $13.68 down -1.30% from its previous closing price of $13.86. In other words, the price has decreased by -$1.30 from its previous closing price. On the day, 1.14 million shares were traded. RDY stock price reached its highest trading level at $13.86 during the session, while it also had its lowest trading level at $13.64.
Ratios:
For a deeper understanding of Dr. Reddy’s Laboratories Ltd. ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.35 and its Current Ratio is at 1.85. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.03.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RDY now has a Market Capitalization of 11394836480 and an Enterprise Value of 3708809728. As of this moment, Dr.’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.75, and their Forward P/E ratio for the next fiscal year is 21.96. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.86 while its Price-to-Book (P/B) ratio in mrq is 2.83. Its current Enterprise Value per Revenue stands at 0.011 whereas that against EBITDA is 0.042.
Stock Price History:
The Beta on a monthly basis for RDY is 0.35, which has changed by -0.10116732 over the last 52 weeks, in comparison to a change of 0.19182634 over the same period for the S&P500. Over the past 52 weeks, RDY has reached a high of $16.17, while it has fallen to a 52-week low of $12.26. The 50-Day Moving Average of the stock is -1.62%, while the 200-Day Moving Average is calculated to be -3.64%.
Shares Statistics:
For the past three months, RDY has traded an average of 1.11M shares per day and 857960 over the past ten days. A total of 834.61M shares are outstanding, with a floating share count of 832.36M. Insiders hold about 0.00% of the company’s shares, while institutions hold 13.13% stake in the company. Shares short for RDY as of 1765756800 were 10105577 with a Short Ratio of 9.13, compared to 1763078400 on 8051861. Therefore, it implies a Short% of Shares Outstanding of 10105577 and a Short% of Float of 2.3599999.
Dividends & Splits
According to the company, the forward annual dividend rate for RDY is 0.09, from 8.0 in the trailing year. Against a Trailing Annual Dividend Yield of 0.5772006. The stock’s 5-year Average Dividend Yield is 0.72. . The current Payout Ratio is 8.90% for RDY, which recently paid a dividend on 2025-07-25 with an ex-dividend date of 2025-07-25. Stock splits for the company last occurred on 2024-11-05 when the company split stock in a 5:1 ratio.
Earnings Estimates
Analysts are recommending an EPS of between $61.53 and $61.53 for the fiscal current year, implying an average EPS of $61.53. EPS for the following year is $56.62, with 1.0 analysts recommending between $56.62 and $56.62.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $84.02B this quarter.It ranges from a high estimate of $89.02B to a low estimate of $80.47B. As of . The current estimate, Dr. Reddy’s Laboratories Ltd. ADR’s year-ago sales were $83.59BFor the next quarter, 8 analysts are estimating revenue of $83.36B. There is a high estimate of $85.07B for the next quarter, whereas the lowest estimate is $79.24B.
A total of 38 analysts have provided revenue estimates for RDY’s current fiscal year. The highest revenue estimate was $372.71B, while the lowest revenue estimate was $325.18B, resulting in an average revenue estimate of $342.02B. In the same quarter a year ago, actual revenue was $325.54BBased on 35 analysts’ estimates, the company’s revenue will be $349.24B in the next fiscal year. The high estimate is $408.94B and the low estimate is $321.22B.
